Company intelligence / Profile preview

Legend Star

Somerset, New Jersey, United Stateslegendstar.cn ↗

Ownership: Private
Employees: ~1533
Development stage: Other

Overview

Legend Biotech has achieved commercial-stage success with its lead product, CARVYKTI® (ciltacabtagene autoleucel), a BCMA-directed CAR-T cell therapy for multiple myeloma. The company recently reported groundbreaking 5-year survival data at ASCO 2025. Its pipeline includes additional next-generation cellular therapies targeting both hematological malignancies and solid tumors.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyGamma-delta T cell therapyNatural killer (NK) cell-based immunotherapy
Industry: Biotech

Partnerships

Janssen Pharmaceuticals/Johnson & Johnson (co-development/commercialization of ciltacabtagene autoleucel/CARVYKTI®)

Beyond the preview

Go deeper on Legend Star.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legend Star.

Explore the full profile